Monday, July 25, 2016

In Clinical Trials, For-Profit Review Boards Are Taking over for Hospitals. Should They?

July 6, 2016

For years, ethicist Arthur Caplan warned medical researchers that paying businesses to evaluate their clinical trials was a bad idea.

He condemned trials that didn’t rely on hospital or academic review boards — long the gold standard in science — and argued that for-profit review boards were out to make a buck, not protect patients.

Today, Caplan sits on the advisory board of WIRB-Copernicus Group, the largest commercial institutional review board, or IRB, in the country.

He says he had no choice.

Read More…